Abst0324 #ACR22 How close are we to measuring Interferon Signature in clinical practice? NCounter and BioFire assays studied - correlated well we each other Genes: IFI27, IFI44L, IFIT1, RSAD2 SLE higher than RA or FMS, but does not correlate with SLE activity @RheumNow https://t.co/izpFtj9Pcd

Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis @Rheumnow https://t.co/d98HSHnJVE

What if my patient with RA or PsA gets pregnant? @RheumNow #ACR22 Abstract #1786; 34 women 👶 Disease scores improved during #pregnancy and increased #postpartum 👶20-27% of women required a cesarean delivery 👶mean delivery 39-40 weeks gestation 👶 1 NICU admission https://t.co/qYPaB6TcDJ

JAK inhibitors in RA: does their performance vary in the real world? @opal_ltd 🇦🇺: n= 5900 JAKi-treated RA pts, 2015-2021 upa is relatively new in Australia, but amazing how bari and tofa are so similar (same with the data on switching reason too) ABST0274 #ACR22 @RheumNow https://t.co/63PrRVAzk5

Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis Factors for SLE transition: younger age, serositis, dsDNA SSc transition: puffy finger, NFC, or SSc antibodies No studies wo moderate or high risk of bias Limited studies on biomarkers for SLE, need more studies @Rheumnow https://t.co/GofGF8TkCx

Time check!⌚🦉 This roaming clockface helps me navigate through time zones while attending #ACR22 ✈️virtually jetlagged but having fun!🤓 @RheumNow @rheumarhyme @doktora_ging #RheumPix https://t.co/HgTcIyw7ej

Infections in JAKi v TNFi in RA We've seen ORAL Surveillance data What about East Asian pts, with enriched zoster risk? National KOR🇰🇷 insurance data: Bacterial: equal Opportunistic: TNFi worse Zoster: JAKi worse serious zoster a lot more common here! ABST0302 #ACR22 @RheumNow https://t.co/lxsbY1Nf9N

“Conflict, crisis and resolution make a story. A good story has drama where there is desire with danger.” @cuttingforstone author, Dr. Verghese noted the COVID19 #pandemic has all of these elements. It is a good story, but we don’t know the resolution. @Rheumnow #ACR22 https://t.co/Tomev2SYcT

Let’s do this #ACR22 ⁦@RheumNow⁩ #rheumpix https://t.co/zTx4TynK44

AS, Lupus and Subclinical RA: What I'm looking forward to at #ACR22 There are three areas that always draw my attention each conference and this time is no different... https://t.co/1h7NRgcqCm https://t.co/9P1UwrmjxW

Progression from non-radiographic to radiographic AxSpA is not the norm ● 16% progress over 5 years, 10-25% over 10 years ● Syndesmophytes in 20% over 4 years ● Male, MRI+ at baseline, response to NSAIDs are predictors of progression Jose U Scher, Review @RheumNow #ACR22 https://t.co/FatodINTfn